PULMONARY FIBROSIS, INTERSTITIAL LUNG DISEASE
Clinical trials for PULMONARY FIBROSIS, INTERSTITIAL LUNG DISEASE explained in plain language.
Never miss a new study
Get alerted when new PULMONARY FIBROSIS, INTERSTITIAL LUNG DISEASE trials appear
Sign up with your email to follow new studies for PULMONARY FIBROSIS, INTERSTITIAL LUNG DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New inhaled therapy aims to slow lung scarring in progressive fibrosis
Disease control Recruiting nowThis study tests an inhaled version of the drug pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their u…
Matched conditions: PULMONARY FIBROSIS, INTERSTITIAL LUNG DISEASE
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated May 26, 2026 06:15 UTC
-
Could a new pill stop lung scarring from getting worse?
Disease control Recruiting nowThis study tests a drug called senicapoc to see if it can prevent lung scarring from getting worse in people with progressive fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). About 140 adults will take either senicapoc or a placebo for 26 weeks. Re…
Matched conditions: PULMONARY FIBROSIS, INTERSTITIAL LUNG DISEASE
Phase: PHASE2 • Sponsor: Vejle Hospital • Aim: Disease control
Last updated May 07, 2026 18:43 UTC